Skip to content
DataLookout
Menu

NCT04895722

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 109 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 33 words Show 6 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Aug 6, 2026 to Aug 7, 2026
    • Interventions: MK-4830 (Biological), Pembrolizumab (Biological), Pembrolizumab/Favezelimab (Biological), Pembrolizumab/Quavonlimab (Biological)… to MK-4830 (Biological), Pembrolizumab (Biological), Pembrolizumab/Favezelimab (Biological), Pembrolizumab/Quavonlimab (Biological)…
    • Secondary endpoints: details revised at 8 of 8 entries
    • Site details revised at 11 of 109 sites
    • Publications: details revised at 1 of 1 entry
  2. Minor Study completion date: Aug 13, 2026 to Aug 6, 2026
    • Study title revised
    v108
  3. Notable Results first posted: Jun 8, 2026
    • Trial arms changed: 5 → 7
    • Secondary endpoints revised (8)
    • Primary endpoint revised
    v107
  4. Minor Secondary endpoints: details revised at 8 of 8 entriesv106
  5. Minor Study completion date: Jun 25, 2026 to Aug 13, 2026v105
Show 44 earlier versionsHide 44 earlier versions
  1. Minor Study completion date: Apr 30, 2026 to Jun 25, 2026v104
  2. Minor Enrollment target: estimated 320 to confirmed 302
    • Primary completion date changed from estimate of Jun 30, 2026 to May 21, 2025
    • Study completion date: Jun 30, 2027 to Apr 30, 2026
    v103
  3. Notable Primary completion date: Oct 20, 2025 to Jun 30, 2026
    • Study completion date: Nov 18, 2025 to Jun 30, 2027
    v102
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 109 of 109 sites
    v100
  5. Minor Study sites revised (109)v99
  6. Minor Site details revised at 1 of 109 sitesv98
  7. Minor Study sites: 108 to 109v97
  8. Minor Site details revised at 1 of 108 sitesv96
  9. Minor Primary completion date: Sep 28, 2025 to Oct 20, 2025
    • Study completion date: Oct 28, 2025 to Nov 18, 2025
    v95
  10. Minor Study sites revised (108)v94
  11. Minor Site details revised at 5 of 108 sitesv93
  12. Minor Site details revised at 2 of 108 sitesv92
  13. Minor Site contacts updated at 1 of 108 sitesv91
  14. Minor Site details revised at 1 of 108 sitesv90
  15. Minor Site details revised at 3 of 108 sitesv89
  16. Minor Site details revised at 2 of 108 sitesv88
  17. Minor Site details revised at 2 of 108 sitesv87
  18. Minor Study sites: 106 to 108v86
  19. Minor Site details revised at 1 of 106 sitesv85
  20. Minor Site details revised at 2 of 106 sitesv84
  21. Minor Site details revised at 2 of 106 sitesv83
  22. Minor Site details revised at 1 of 106 sitesv82
  23. Minor Site details revised at 3 of 106 sitesv81
  24. Minor Site details revised at 2 of 106 sitesv80
  25. Minor Study sites: 105 to 106v79
  26. Notable Eligibility criteria revised
    • Study sites: 103 to 105
    • Study title revised
    v78
  27. Minor Site details revised at 1 of 103 sitesv77
  28. Minor Site details revised at 1 of 103 sitesv76
  29. Minor Study sites: 102 to 103v75
  30. Minor Study sites: 100 to 102v74
  31. Minor Study sites: 98 to 100v73
  32. Minor Study sites: 95 to 98v72
  33. Minor Study sites: 94 to 95v71
  34. Minor Study sites: 93 to 94v70
  35. Minor Site details revised at 1 of 93 sitesv69
  36. Minor Study sites: 90 to 93v68
  37. Minor Study sites: 87 to 90v67
  38. Minor Study sites: 86 to 87v66
  39. Minor Study sites: 84 to 86v65
  40. Minor Study sites: 83 to 84v64
  41. Minor Study sites: 82 to 83v63
  42. Minor Study sites: 81 to 82v62
  43. Minor Study sites: 79 to 81v61
  44. Minor Study sites: 76 to 79v60
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Timeframe: Up to approximately 46 months

Secondary (8)

Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR
PFS Per RECIST 1.1 as Assessed by Investigator
ORR Per RECIST 1.1 as Assessed by Investigator
DOR Per RECIST 1.1 as Assessed by Investigator
Show 3 moreShow less
Overall Survival (OS)
Number of Participants Who Experienced an Adverse Event (AE)
Number of Participants Discontinuing Study Treatment Due to an AE

Arms and interventions

Cohort A - Pembrolizumab/QuavonlimabExperimental

Participants in Cohort A receive co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) every 6 weeks (Q6W) for up to approximately 2 years.

Cohort A - PembrolizumabActive comparator

Participants in Cohort A receive pembrolizumab 400 mg intravenously (IV) Q6W for up to approximately 2 years.

Cohort B - Pembrolizumab/QuavonlimabExperimental

Participants received co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) Q6W for up to approximately 2 years.

Cohort B - Pembrolizumab Plus MK-4830Experimental

Participants receive pembrolizumab 200 mg plus MK-4830 800 mg Q3W for up to approximately 2 years.

Cohort B - Pembrolizumab/FavezelimabExperimental

Participants receive co-formulated pembrolizumab/favezelimab (200 mg/800 mg) every 3 weeks (Q3W) for up to approximately 2 years.

Cohort B - Pembrolizumab/VibostolimabExperimental

Participants receive co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) Q3W for up to approximately 2 years.

Cohort B - PembrolizumabActive comparator

Participants in Cohort B receive pembrolizumab 400 mg IV Q6W for up to approximately 2 years.

Biologicals: Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830

Sites

109 sites in 22 countries

United States 11, Spain 8, Colombia 7, Germany 7, South Korea 7, France 6, Hungary 6, Poland 6, Russia 6, Belgium 5, Guatemala 5, Turkey (Türkiye) 5, Denmark 4, Greece 4, Romania 4, United Kingdom 4, Canada 3, Italy 3, Lithuania 3, Costa Rica 2, Estonia 2, Netherlands 1